Effects of Sitagliptin on HbA1c levels in uncontrolled hyperglycemia in diabetics using conventional OAD’s.

Abstract

Objectives: The study anticipates to appraise HbA1c levels after three months of sitagliptin addition (100mg/day) to patients already using conventional oral antidiabetics in patients of type II diabetes mellitus who have a meager retort to these existing anti diabetics. Study Design: Mainly cross sectional prospective multicenter, open labeled study. Setting: Department of Medicine University medical diagnostic center & District Head Quarter Hospital Sargodha. Period: January 2017 to June 2017. Material & Methods: 100 inadequately controlled diabetics using different types of oral anti diabetics were chosen and an especially designed performa was accomplished. In our study we gave preference to those patients who were on preexisting oral anti diabetics and now dipeptidyl peptidase 4 inhibitors were added for the first time. The patients were instructed (at the baseline visit) to report during the subsequent visit about glycemic control. Patients were not clued-up that glycosylated hemoglobin control was the main seek of the study, so there was no chance for Pygmalion effect. Results: Levels of glycosylated hemoglobin were significantly reduced after three months of treatment compared to baseline, with a mean alteration in HbA1c level from baseline of −0.77% (range, −0.68 to − -0.86%) in the entire study population at three months. The percentage of patients who achieved an HbA1c level of <6.9% significantly increased after three months of treatment, reaching 58.1%. Conclusion: HbA1c significantly lowered in patients with type 2 diabetes mellitus on conventional OADs after adding sitagliptin.